Search Results - "Kinon, B."

Correlates of late-onset antipsychotic treatment resistance by Fonseca De Freitas, D., Agbedjro, D., Kadra-Scalzo, G., Francis, E., Ridler, I., Pritchard, M., Shetty, H., Segev, A., Casetta, C., Smart, S., Morris, A., Downs, J., Christensen, S., Bak, N., Kinon, B., Stahl, D., Hayes, R., Maccabe, J.

“…IntroductionThere is emerging evidence of heterogeneity within treatment-resistance schizophrenia (TRS), with some people not responding to antipsychotic…”
Get full text

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers by Cecchi, M., Adachi, M., Basile, A., Buhl, D.L., Chadchankar, H., Christensen, S., Christian, E., Doherty, J., Fadem, K.C., Farley, B., Forman, M.S., Honda, S., Johannesen, J., Kinon, B.J., Klamer, D., Marino, M.J., Missling, C., O'Donnell, P., Piser, T., Puryear, C.B., Quirk, M.C., Rotte, M., Sanchez, C., Smith, D.G., Uslaner, J.M., Javitt, D.C., Keefe, R.S.E., Mathalon, D., Potter, W.Z., Walling, D.P., Ereshefsky, L.

“…Complexity and lack of standardization have mostly limited the use of event-related potentials (ERPs) and quantitative EEG (QEEG) biomarkers in drug…”
Get full text

The heterogeneity of antipsychotic response in the treatment of schizophrenia by Case, M, Stauffer, V L, Ascher-Svanum, H, Conley, R, Kapur, S, Kane, J M, Kollack-Walker, S, Jacob, J, Kinon, B J

“…Schizophrenia is a heterogeneous disorder in terms of patient response to antipsychotic treatment. Understanding the heterogeneity of treatment response may…”
Get more information

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia by Kinon, Bruce J, Chen, Lei, Ascher-Svanum, Haya, Stauffer, Virginia L, Kollack-Walker, Sara, Sniadecki, Jennifer L, Kane, John M

“…Abstract Objective To test whether early onset of response to antipsychotic medications accurately predicts subsequent response in the treatment of patients…”
Get full text

The different trajectories of antipsychotic response: antipsychotics versus placebo by Marques, T R, Arenovich, T, Agid, O, Sajeev, G, Muthén, B, Chen, L, Kinon, B J, Kapur, S

“…It is generally accepted that antipsychotics are more effective than placebo. However, it remains unclear whether antipsychotics induce a pattern or trajectory…”
Get more information

Long-term olanzapine treatment : Weight change and weight-related health factors in schizophrenia by KINON, Bruce J, BASSON, Bruce R, GILMORE, Julie A, TOLLEFSON, Gary D

“…Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in…”
Get full text

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects by Halbreich, U., Kinon, B.J., Gilmore, J.A., Kahn, L.S.

“…The neurologic processes involved in schizophrenia are complex and diverse and the mechanisms through which antipsychotic agents exert their effects have been…”
Get full text

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia by Fijal, B A, Kinon, B J, Kapur, S, Stauffer, V L, Conley, R R, Jamal, H H, Kane, J M, Witte, M M, Houston, J P

“…Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with…”
Get full text

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone by BASSON, Bruce R, KINON, Bruce J, TAYLOR, Cindy C, SZYMANSKI, Keith A, GILMORE, Julie A, TOLLEFSON, Gary D

“…Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine,…”
Get full text

Mechanisms of action of atypical antipsychotic drugs: a critical analysis by Kinon, B J, Lieberman, J A

“…Various criteria used to define atypical antipsychotic drugs include: 1) decrease, or absence, of the capacity to cause acute extrapyramidal motor side effects…”
Get full text

Pharmacogenetic analysis of the mGlu2 3 agonist LY2140023 monohydrate in the treatment of schizophrenia by Liu, W, Downing, A C M, Munsie, L M, Chen, P, Reed, M R, Ruble, C L, Landschulz, K T, Kinon, B J, Nisenbaum, L K

“…The goal of this study was to identify genetic markers associated with LY2140023 monohydrate response in patients with schizophrenia. Variants in eight…”
Get full text

Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity by Lieberman, Jeffrey A., Sheitman, Brian B., Kinon, Bruce J.

“…Existing pathophysiological models of schizophrenia are limited in their ability to account for all the clinical dimensions of the disorder. The purpose of…”
Get full text

Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being by Naber, D, Kollack-Walker, S, Chen, J, Stauffer, V L, Kinon, B J, Case, M, Ascher-Svanum, H, Kapur, S, Kane, J M

“…The aim of this study was to determine what variables predict a 'combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. This analysis…”
Get more information

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia by Ascher-Svanum, Haya, Nyhuis, Allen W., Faries, Douglas E., Kinon, Bruce J., Baker, Robert W., Shekhar, Anantha

“…Objective: Early nonresponse to antipsychotics appears to predict subsequent nonresponse to treatment when assessed in randomized controlled trials of…”
Get full text

Weight change and atypical antipsychotic treatment in patients with schizophrenia by Jones, B, Basson, B R, Walker, D J, Crawford, A M, Kinon, B J

“…Schizophrenic patients who have been prescribed atypical antipsychotics have a potential risk of gaining weight. The implications of weight gain for clinical…”
Get full text

Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial by Kennedy, J. S., Jeste, D., Kaiser, C. J., Golshan, S., Maguire, G. A., Tollefson, G., Sanger, T., Bymaster, F. P., Kinon, B. J., Dossenbach, M., Gilmore, J. A., Breier, A.

“…Objectives To compare the six‐week clinical response and safety profile of schizophrenia patients, age ≥60 years, receiving olanzapine (OLZ) vs haloperidol…”
Get full text

S.01.01 Are metabotropic glutamate receptors new targets for antipsychotics? by Kinon, B, Zhang, L, Breier, A

Get full text

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine by KINON, Bruce J, BASSON, Bruce R, GILMORE, Julie A, MALCOLM, Sandra, STAUFFER, Virginia L

“…This study compared the efficacy and safety of 4 therapeutically relevant strategies for switching clinically stable patients from a conventional antipsychotic…”
Get full text

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia by David, Stacy R., Taylor, Cindy C., Kinon, Bruce J., Breier, Alan

“…There is relatively little comparative information on elevations in plasma prolactin level (PRL) with conventional versus novel antipsychotic agents. This…”
Get full text

S.05.03 The inherent trajectories in antipsychotic response: beyond simple responders and non-responders by Kapur, S, Arenovich, O, Agid, O, Muthen, B, Chen, L, Kinon, B

Get full text